Sitagliptin for the Treatment of Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients newly diagnosed with T2D will be recruited and will receive sitagliptin treatment for 3 months. The gut microbiome of the participants before and after the treatment and the effectiveness of sitagliptin treatment on type 2 diabetes will be evaluated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patients 18-65 years old newly diagnosed with type 2 diabetes

• HbA1c ≥ 7%

Exclusion Criteria:

• The positive of diabetes antibodies

• Anti-diabetic drugs therapy before participation

• Pancreatitis

• Coronary artery disease

• Liver function impairment

• Renal function impairment

• History of intestinal surgery

• Chronic hypoxic diseases (emphysema and cor pulmonale)

• Infectious disease

• Hematological disease

• Systemic inflammatory disease

• Cancer

• Pregnant

• Ingesting agents known to influence glucose or lipid metabolism;

• Any antibiotics or probiotics in the past three months prior to the study.